Novo Nordisk
Note: This is a daily stock update and the information stands true as of 27/01/25, 09:00 CET.
Company update:
On Friday, news on Amycretin a new weight loss drug candidate was favorable. Amycretin, with its highest dose (20mg) produced c.22% weight-loss in 36 weeks in phase Ib/2a trial. The drug also has promising potential for its oral version which is in early stage trial.
This is encouraging and demonstrates that OVO still has a lot of room to grow in the weight loss business.
Expert opinion:
I think Novo is a clear buy. Following its massive drop, valuation is back to more attractive levels with PE25 at 22.7 down to 18.1x in 2026. We believe the earnings momentum is likely to remain very strong. While the competition will increase eventually, the market remains essentially duopolistic with Eli Lily. At these levels, Novo Nordisk is a stock to buy and hold over the long run.
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Subscribe to our blog
Alphavalue Morning Market Tip
Solid start of 2025 with signs of recovery in key markets.